Moderna, Thermo Fisher partner to manufacture Covid vaccine, other drugs

Thermo Fisher had already partnered with Moderna last year to help scale up production of its Covid vaccine, branded as Spikevax

Moderna
Moderna Covid-19 vaccine
Reuters
1 min read Last Updated : Feb 23 2022 | 8:04 PM IST
Moderna Inc has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its Covid-19 vaccine and other experimental medicines based on mRNA technology, the companies said on Wednesday.

Thermo Fisher had already partnered with Moderna last year to help scale up production of its Covid vaccine, branded as Spikevax.

As a part of the 15-year expanded deal, Thermo Fisher would provide dedicated manufacturing capacity in the United States for fill/finish services as well as labeling and packaging services for Spikevax and other mRNA drugs in Moderna's pipeline.

Moderna's vaccine received full US approval in January for adults and is cleared for use in more than 70 countries.

The company last week said it was developing three new vaccines based on the same messenger RNA (mRNA) technology used for its COVID-19 shot, including one for viral infection shingles.

On Tuesday, Moderna also announced a partnership with Adium Pharma S.A. for the distribution of its vaccine in Latin America.

Moderna is set to report its fourth-quarter results on Thursday.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineVaccine

Next Story